Abstract
There is increasing evidence regarding the optimal therapeutic strategies for multidrug-resistant (MDR) bacteria that cause common infections and are resistant to existing antibiotics. Combination therapies, such as β-lactam combined with β-lactamase inhibitors or combination antibiotics, is a therapeutic strategy to overcome MDR bacteria. In recent years, the therapeutic options have expanded as certain combination drugs have been approved in more countries. However, only a handful of guidelines support these options, and the recommendations are based on low-quality evidence. This review describes the significance and efficacy of combination therapy as a therapeutic strategy against Gram-negative MDR pathogens based on previously reported meta-analyses.
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference72 articles.
1. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021https://apps.who.int/iris/rest/bitstreams/1350455/retrieve
2. Surveillance of Antimicrobial Resistance in Europe, 2020 Datahttps://www.ecdc.europa.eu/sites/default/files/documents/Surveillance-antimicrobial-resistance-in-Europe-2020.pdf
3. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
4. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献